✦ LIBER ✦

Evaluation of the costs and efficacy of vinorelbine-cisplatin combination in nonsmall cell lung cancer — A developing country model

✍ Scribed by Ozturk, C; Kokturk, N; Sener, M; Levent, E

Book ID: 118569834
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 118 KB
Volume: 29
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(00)80289-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of the combination of vin

Phase II study of the combination of vinorelbine and cisplatin in advanced non-small-cell lung cancer

✍ Kiyoshi Mori; Yukari Kamiyama; Tetsuro Kondo; Yasuhiko Kano; Keigo Tominaga 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 169 KB

Trimetrexate combined with cisplatin or

Trimetrexate combined with cisplatin or etoposide in the treatment of nonsmall cell lung cancer: A pilot study

📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 155 KB

PCNI6 COMPARATIVE COSTS OF GEMCITABINE/C

PCNI6 COMPARATIVE COSTS OF GEMCITABINE/CISPLATIN, PACLITAXEL/CARBOPLATIN AND VINORELBINE/CISPLATIN IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN GERMANY

✍ H Bischoff; M Hamann; G Stynes; S Bhalla; D Tilden; A Kielhorn 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB

Combination of cisplatin, ifosfamide and

Combination of cisplatin, ifosfamide and vinorelbine in phase II trial in advanced non-small cell lung cancer (NSCLC)

✍ Barón, FJ; Ceuva, JF; Vázquez, F; Candamio, S; Calvo, M; Menéndez, MD; Irigoyen, 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 252 KB

Phase II study of the combination of vin

Phase II study of the combination of vinorelbine, cisplatin, and tirapazamine in inoperable non-small cell lung cancer (NSCLC)

✍ Le Chevalier, T; Gatineau, M; Daniel, C; Rixe, O; Pailler, M.-C; Fizazi, K; Font 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 105 KB

A phase I-II study of docetaxel-ifosfami

A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer

✍ Christos Kosmas; Nicolas B. Tsavaris; Thomas Makatsoris; Adimchi Onyenadum; Mari 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 96 KB 👁 1 views

## Abstract In an attempt to develop more effective chemotherapy regimens in advanced nonsmall cell lung cancer (NSCLC), we evaluated docetaxel‐ifosfamide‐cisplatin (DIP) based on our previous experience with paclitaxel‐ifosfamide‐cisplatin. Patients with advanced NSCLC (stages III‐IV), WHO‐PS≤2, n